Pre-clinical toxicology studies and prompt material delivery are essential for IND and CTA approvals, crucial for advancing drug candidates to clinical trials.
CAR-T therapies come with boxed warnings of serious neurotoxic side effects. Now, growing concerns over parkinsonism have led to a clinical trial halt.